Losartan Reduces Insulin Resistance by Inhibiting Oxidative Stress and Enhancing Insulin Signaling Transduction

 

 Buy Article Permissions and Reprints

Abstract

Background: Inhibition of the rennin-angiotensin system (RAS) could reduce insulin resistance in patients with hypertension and diabetic kidney disease (DKD), but whether the effect of losartan on insulin resistance is associated with reduction of oxidative stress and enhancement of insulin signaling transduction has not been fully elucidated.

Methods: 130 patients with type 2 DKD were randomly assigned into 2 groups, the losartan group (n=65, 100 mg orally daily for 12 months) and the amlodipine group (n=65, 10 mg orally daily for 12 months). Oxidative stress markers in plasma, urine concentrations of 8-hydroxy-2’-deoxyguanosine (8-OHdG) and nitrotyrosine (NT) as well as SOD activity were measured by ELISA. After in vitro treatment with different doses of losartan (10, 100 μmol/L) or amlodipine for 48 h, the size of H₂O₂-induced adipocytes and glucose consumption were measured. Western blot was performed to investigate IRS-1 serine phosphorylation level as well as the protein expressions of phosphorylated insulin receptor (pIR), phosphatidylinositol 3- kinase (PI3K) and insulin receptor substrate 1 (IRS-1) in 3T3-L1 adipocytes.

Results: After 12-month treatment, there were no significant differences in systolic and diastolic blood pressures decreases, plasma fasting blood glucose and HbA1c between the 2 groups. Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced. There were significant positively correlations of HOMA-IR with inflammatory oxidative stress markers. In vitro study showed that losartan could increase glucose uptake in 3T3-L1 adipocytes (P<0.01) and decrease adipocyte size (P<0.01), while amlodipine can’t. Losartan can also enhance adiponectin (P<0.05) and decrease TNF-α (P<0.05) and IL-6 (P<0.01) secretion, while amlodipine can’t. The protein expressions of pIR, IRS-1 and PI3K were significantly increased after treatment with losartan (P<0.01), while the level of IRS-1 serine phosphorylation was decreased (P<0.01), which could be blocked by specific PI3K inhibitor wortmannin.

Conclusions: These results suggest that the effect of losartan on insulin resistance is associated with the reduction of oxidative stress and inflammation in patients with type 2 DKD as well as the activation of insulin signal pathway in insulin-resistance 3T3-L1 adipocytes through modulation of PI3K pathway. (Clinical Trials. gov number, NCT 00774904)

^* Qiao QY and Pan Y contributed equally to this paper.

• References

• 1 Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449-465
  CrossrefPubMedGoogle Scholar
• 2 Satoh M, Fujimoto S, Haruna Y et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288: F1144-F1152
  CrossrefPubMedGoogle Scholar
• 3 Gorin Y, Block K, Hernandez J et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280: 39616-39626
  CrossrefPubMedGoogle Scholar
• 4 Fujita H, Sakamoto T, Komatsu K et al. Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res 2011; 34: 1302-1308
  CrossrefPubMedGoogle Scholar
• 5 Booth GL, Kapral MK, Fung K et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36
  CrossrefPubMedGoogle Scholar
• 6 Crutchlow MF, Robinson B, Pappachen B et al. Validation of steady-state insulin sensitivity indices in chronic kidney disease. Diabetes Care 2007; 30: 1813-1818
  CrossrefPubMedGoogle Scholar
• 7 Engeli S, Gorzelniak K, Kreutz R et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17: 555-560
  CrossrefPubMedGoogle Scholar
• 8 Cassis LA, Police SB, Yiannikouris F et al. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008; 10: 93-98
  CrossrefPubMedGoogle Scholar
• 9 Tian F, Luo R, Zhao Z et al. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010; 118: 258-265
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Mor A, Aizman E, George J et al. RAS inhibition induces insulin sensitivity and glucose uptake. PloS One 2011; 6: e21712
  CrossrefPubMedGoogle Scholar
• 11 Aksnes TA, Flaa A, Sevre K et al. Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade. Blood Press 2008; 17: 156-163
  CrossrefPubMedGoogle Scholar
• 12 Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81
  CrossrefPubMedGoogle Scholar
• 13 Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009; 24: 1876-1883
  CrossrefPubMedGoogle Scholar
• 14 Lee MH, Song HK, Ko GJ et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890-900
  CrossrefPubMedGoogle Scholar
• 15 Furuhashi M, Ura N, Takizawa H et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982
  CrossrefPubMedGoogle Scholar
• 16 Younis F, Stern N, Limor R et al. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism 2010; 59: 1200-1209
  CrossrefPubMedGoogle Scholar
• 17 Cole BK, Keller SR, Wu R et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010; 55: 715-721
  CrossrefPubMedGoogle Scholar
• 18 Muñoz MC, Giani JF, Dominici FP et al. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 2009; 27: 2409-2420
  CrossrefPubMedGoogle Scholar
• 19 Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the Assessment of Insulin sensitivity. Diabetes Care 2000; 23: 57-63
  CrossrefPubMedGoogle Scholar
• 20 Sakoda H, Ogihara T, Anai M et al. Dexamethasone-induced insulin resistance in 3T3L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000; 49: 1700-1708
  CrossrefPubMedGoogle Scholar
• 21 Guo H, Ling W, Wang Q et al. Cyanidin 3-glucoside protects 3T3-L1 adipocytes against H2O2- or TNF-alpha-induced insulin resistance by inhibiting c-Jun NH2-terminal kinase activation. Biochem Pharmacol 2008; 75: 1393-1401
  CrossrefPubMedGoogle Scholar
• 22 Zou J, Li Y, Fan HQ et al. Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells. BMC Res Notes 2012; 5: 168
  CrossrefPubMedGoogle Scholar
• 23 Wu LL, Chiou CC, Chang PY et al. Urinary 8-OhdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1-9
  CrossrefPubMedGoogle Scholar
• 24 Son SM. Reactive Oxygen and Nitrogen Species in Pathogenesis of Vascular Complications of Diabetes. Diabetes Metab J 2012; 36: 190-198
  CrossrefPubMedGoogle Scholar
• 25 Fujita H, Fujishima H, Chida S et al. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 2009; 20: 1303-1313
  CrossrefPubMedGoogle Scholar
• 26 Arozal W, Watanabe K, Veeraveedu PT et al. Effects of Angiotensin Receptor Blocker on Oxidative Stress and Cardio-Renal Function in Streptozotocin-Induced Diabetic Rats. Biol Pharm Bull 2009; 32: 1411-1416
  CrossrefPubMedGoogle Scholar
• 27 Fan Q, Liao J, Kobayashi M et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020
  CrossrefPubMedGoogle Scholar
• 28 Nakamura A, Shikata K, Nakatou T et al. Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy. J Diabetes Investig 2013; 4: 195-201
  CrossrefPubMedGoogle Scholar
• 29 Ogawa S, Kobori H, Ohashi N et al. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic nephropathy. Biomark Insights 2009; 4: 97-102
  PubMedGoogle Scholar
• 30 Ogawa S, Mori T, Nako K et al. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy. Hypertension 2006; 47: 699-705
  CrossrefPubMedGoogle Scholar
• 31 Kayabasi H, Yilmaz Z, Sit D et al. The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis. Eur Rev Med Pharmacol Sci 2013; 17: 235-242
  PubMedGoogle Scholar
• 32 Clasen R, Schupp M, Foryst-Ludwig A et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143
  CrossrefPubMedGoogle Scholar
• 33 Watanabe S, Okura T, Kurata M et al. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther 2006; 28: 1677-1685
  CrossrefPubMedGoogle Scholar
• 34 Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415
  CrossrefPubMedGoogle Scholar
• 35 Heydrick SJ, Gautier N, Olichon-Berthe C et al. Early alteration of insulin stimulation of PI 3-kinase in muscle and adipocyte from gold thioglucose obese mice. Am J Physiol 1995; 268: E604-E612
  PubMedGoogle Scholar
• 36 Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009; 9: 753-762
  CrossrefPubMedGoogle Scholar
• 37 Sevillano J, de Castro J, Bocos C et al. Role of insulin receptor substrate-1 serine 307 phosphorylation and adiponectin in adipose tissue insulin resistance in late pregnancy. Endocrinology 2007; 148: 5933-5942
  CrossrefPubMedGoogle Scholar
• 38 Maiuri T, Ho J, Stambolic V. Regulation of adipocyte differentiation by distinct subcellular pools of protein kinase B (PKB/Akt). J Biol Chem 2010; 285: 15038-15047
  CrossrefPubMedGoogle Scholar